Enzolytics Inc. (OTCMKTS: ENZC) gained 13.5% in no news. Recently the company finalized definitive plans to move its previously evaluated ITV-1 anti-HIV therapeutics into clinical studies and distribution across Europe. The completion of the steps will make the anti-HIV therapy a vital source of revenue for the Enzolytics.
It will be a significant milestone for its profitability and human health as well. Enzolytics has established International Medical Partners Ltd through collaboration with its European partners, which will have a license to distribute the ITV-1 therapeutics across Europe in markets covered by the EMA. The anti-HIV therapy had earlier advanced into certification through the Bulgarian Drug Agency.
The company also announced a coherent protocol it is planning to execute to meet its goal of producing a therapeutic HIV cure and a planned protocol addressing current and future pandemics. The definition of the protocol is due to Enzolytics’ collaboration with Intel Corp to use AI in accelerating drug discoveries and development. So in the coming months, ENZC is a stock to watch.
Market Reaction:
On Friday, ENZC stock jumped 13.42% at $0.1927 with more than 35.50 million shares, compared to its average volume of 30.98 million shares. The stock had moved within a range of $0.1650 – 0.2150after opening the trade at $0.1650. Over the past 52-week, the stock has been trading within a range of $0.0003 – 0.9580.
 Stock Attempts To Recover: What Next?){kind=link}